CA2405728A1 - Conjugue lipides-peptides pour le traitement du cancer - Google Patents

Conjugue lipides-peptides pour le traitement du cancer Download PDF

Info

Publication number
CA2405728A1
CA2405728A1 CA002405728A CA2405728A CA2405728A1 CA 2405728 A1 CA2405728 A1 CA 2405728A1 CA 002405728 A CA002405728 A CA 002405728A CA 2405728 A CA2405728 A CA 2405728A CA 2405728 A1 CA2405728 A1 CA 2405728A1
Authority
CA
Canada
Prior art keywords
peptide
leu
tyr
lys
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002405728A
Other languages
English (en)
Inventor
Anand C. Burman
Sudhanand Prasad
Rama Mukherjee
Manu Jaggi
Anu T. Singh
Rajan Sharma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Dabur Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dabur Research Foundation filed Critical Dabur Research Foundation
Publication of CA2405728A1 publication Critical patent/CA2405728A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur de nouveaux peptides antiprolifération et antisécrétoires inhibiteurs du récepteur des peptides intestinaux vasoactifs (VIP) et utilisables pour le traitement du cancer, et en particulier sur la synthèse de conjugués lipides-peptides contenant des acides gras de différentes tailles, et qui inhibent la fixation des VIPs à leurs récepteurs. L'invention porte en outre sur les procédés d'élaboration de ces peptides, sur des préparations les contenant et sur des applications pharmacologiques de ces peptides spécialement destinées au traitement et à la prévention du cancer.
CA002405728A 2000-07-31 2000-07-31 Conjugue lipides-peptides pour le traitement du cancer Abandoned CA2405728A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2000/020876 WO2002010193A1 (fr) 2000-07-31 2000-07-31 Conjugue lipides-peptides pour le traitement du cancer

Publications (1)

Publication Number Publication Date
CA2405728A1 true CA2405728A1 (fr) 2002-02-07

Family

ID=21741642

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405728A Abandoned CA2405728A1 (fr) 2000-07-31 2000-07-31 Conjugue lipides-peptides pour le traitement du cancer

Country Status (4)

Country Link
EP (1) EP1409519A1 (fr)
AU (1) AU2000265054A1 (fr)
CA (1) CA2405728A1 (fr)
WO (1) WO2002010193A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529125A1 (fr) 2003-06-19 2004-12-23 Yeda Research & Development Co. Ltd. Lipopeptides antimicrobiens et anticancereux
JP7341451B2 (ja) * 2016-02-01 2023-09-11 エピアクシス セラピューティクス プロプライアタリー リミティド タンパク質性化合物とその利用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
US5217953A (en) * 1990-11-30 1993-06-08 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Vasoactive intestinal peptide antagonist
US5565424A (en) * 1994-02-07 1996-10-15 Ramot - University Authority For Applied Research And Industrial Development Ltd. Superactive VIP antagonists
EP1126871A2 (fr) * 1998-10-16 2001-08-29 The Government of The United States of America, as represented by The Department of Health and Human Services Therapie combinee avec antagoniste du polypeptide vasoactif intestinal

Also Published As

Publication number Publication date
EP1409519A1 (fr) 2004-04-21
WO2002010193A1 (fr) 2002-02-07
AU2000265054A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
JP2744910B2 (ja) ペプチド誘導体類
FI94350B (fi) Menetelmä T-soluavustaja-aktiivisuutta omaavien peptidien valmistamiseksi
IL277483B1 (en) New anti-GLP-1 analogs
NO302619B1 (no) Analogifremgangsmåte for fremstilling av et terapeutisk peptid
LV10108B (en) Inhibitors of cells proliferation, pharmaceutical composition, process of producing of compounds, methods of inhibition of cellular proliferation
US7060678B2 (en) Peptides comprising furanoid sugar amino acids for the treatment of cancer
US6828304B1 (en) Peptides for treatment of cancer
EP3096795B1 (fr) Molécules de neurotensine activées et leurs utilisations
US6316414B1 (en) Somatostatin analogs for the treatment of cancer
CA2405704C (fr) Analogues de bombesine utilises dans le traitement du cancer
SK150196A3 (en) Peptides with immunomodulatory effects, pharmaceutical formulations containing them and their use
HU205771B (en) Process for producing irreversible peptide ligands for bombesin receptors and process for producing pharmaceutical compositions comprising such peptides as active ingredient
DK164875B (da) Gonadoliberinderivater og deres farmaceutisk acceptable syreadditionssalte eller metalcomplexer, en fremgangsmaade til fremstilling heraf samt et farmaceutisk praeparat indeholdende disse
EP1198478B1 (fr) Analogues de la somatostatine destines au traitement du cancer
CA2405724C (fr) Analogues de la substance p destines au traitement du cancer
WO2002010193A1 (fr) Conjugue lipides-peptides pour le traitement du cancer
US6596692B1 (en) Substance P analogs for the treatment of cancer
JPH0631314B2 (ja) 新規なゴナドリベリン誘導体
Sakura et al. Structure-activity relationships of neuromedin U. IV. Absolute requirement of the arginine residue at position 7 of dog neuromedin U-8 for contractile activity
US6989371B1 (en) Bombesin analogs for treatment of cancer
SÜLI‐VARGHA et al. Synthesis of N‐(2‐chloroethyl)‐N‐nitrosocarbamoyl derivatives of biologically active polypeptide hormone fragments
JP3109835B2 (ja) ペプシンの放出を抑制するためのペプチド
WO1998043995A1 (fr) Nouveaux complexes anti-vih et compositions medicamenteuses
Abiko et al. Syntheses of neurotensin (nt) analogues and their comparative anorectic effect on food intake in rats
CN101177449A (zh) 叉聚肽,其药物组合物与用途

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued